News Update: Amylin Pharma Climbs After FDA Did Not Ask For Tests On Diabetes Drug

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
47 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Mar 15, 2010

Shares of Amylin Pharmaceuticals (NASDAQ:AMLN) are trading 13.5% higher to $23.00 premarket Monday after the U.S. Food and Drug Administration asked for more information related to existing manufacturing processes, risk management and labeling for the Type 2 diabetes drug Byetta.

Though, the FDA didn't request new tests or information related to quality-control violations identified in a December inspection of the plant where the drug is made.

Category:

News & Politics

Tags:

License:

Standard YouTube License

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more